PE22-28 For Lab Research

Buy PE22-28 Peptide UK – >99% Purity | TREK-1 Inhibitor | Research Use Only

PE22-28 (also known as Mini-Spadin) is a synthetic 7-amino-acid peptide and optimised analog of Spadin, studied as a highly selective TREK-1 potassium channel inhibitor with applications in depression, neurogenesis, and cognitive research models. Buy PE22-28 peptide in the UK from Peptides Lab UK with >99% HPLC-verified purity, batch-specific COA, and fast UK dispatch for laboratory research use only.

What is PE22-28 Peptide?

PE22-28 is a synthetic heptapeptide derived from Spadin (PE12-28), a naturally occurring peptide produced by the cleavage of sortilin — a protein expressed widely in neurons. Spadin was first identified as an endogenous TREK-1 channel blocker with antidepressant properties, but its short half-life in circulation limited its research utility.

PE22-28 was specifically designed to address this limitation. By studying the natural blood degradation products of Spadin, researchers at the University of Nice Sophia Antipolis (France) identified a 7-amino-acid fragment — PE22-28 — that retained and significantly improved upon Spadin’s TREK-1 blocking activity, while demonstrating superior in vivo stability, bioavailability, and duration of action.

This makes PE22-28 one of the most pharmacologically potent and research-relevant TREK-1 inhibitors currently available from UK peptides suppliers.

What is TREK-1, and Why Does It Matter in Research?

TREK-1 (TWIK-related K⁺ channel-1) is a two-pore domain potassium channel expressed throughout the central nervous system. Research has established its involvement in several neurological processes:

• Mood and depression — overexpression of TREK-1 is associated with depressive states in animal models; genetic deletion of TREK-1 renders mice resistant to depression
• Neurogenesis — TREK-1 modulation is linked to hippocampal neurogenesis and the growth of new synaptic connections
• Serotonin regulation — TREK-1 influences serotonin signalling pathways, making it a distinct target from conventional monoamine-based mechanisms
• Neuroprotection — TREK-1 activity has been studied in the context of cerebral ischemia, excitotoxicity, and post-stroke depression models
• Seizure resistance — research has explored how TREK-1 modulation influences neuronal excitability and seizure susceptibility

PE22-28 selectively blocks TREK-1 with high affinity and specificity, making it a preferred research tool for investigating all of the above pathways in controlled laboratory models.

How Does PE22-28 Work?

PE22-28 functions as a selective TREK-1 potassium channel inhibitor. In vitro studies on hTREK-1/HEK cells using patch-clamp technique showed that PE22-28 displayed better specificity and affinity for the TREK-1 channel compared to its parent compound Spadin, with an IC₅₀ of 0.12 nM versus 40–60 nM for Spadin.

When TREK-1 channels are blocked in a research setting, downstream effects observed in pre-clinical models include:

• Serotonin pathway modulation — TREK-1 inhibition influences serotonergic transmission, producing effects in mood-related behavioural models
• Hippocampal neurogenesis stimulation — research indicates PE22-28 promotes the growth of new neurons in the hippocampus, with studies reporting a doubling of neurogenesis biomarkers in treated models
• Synaptogenesis — PE22-28 has been associated with increased synaptic connection formation in hippocampal tissue in pre-clinical models
• Rapid onset of effect — compared to classical antidepressant drugs such as fluoxetine, which require 3–4 weeks for effects to manifest, Spadin-class peptides act rapidly within only 4 days of treatment — a property PE22-28 retains and improves upon
• Selective TREK-1 specificity — PE22-28 does not meaningfully interact with related K2P channels including TREK-2, TRAAK, TRESK, or TASK-1, nor does it affect hERG channel activity, indicating high selectivity

What Does PE22-28 Do in Research?

In pre-clinical laboratory models, PE22-28 has demonstrated a range of neurologically significant effects, making it one of the most studied neuropeptides available from UK peptides research suppliers:

• Depression models — reduces immobility in Forced Swim Test (FST) and Learned Helplessness test in mouse models, consistent with antidepressant activity
• Neurogenesis promotion — shown to robustly stimulate hippocampal neurogenesis and synaptogenesis, with spatial and short-term memory improvements observed in treated models
• Post-stroke depression — research has examined PE22-28 in models of post-stroke depression (PSD), where TREK-1 overexpression is implicated; unlike SSRIs tested alongside it, PE22-28 appeared to reduce depressive markers without associated adverse effects in the model
• Seizure resistance — rather than exacerbating seizure susceptibility (a theoretical concern with TREK-1 inhibition), pre-clinical data showed PE22-28 enhanced resistance to generalised seizures
• Cognitive function — improvements in spatial memory and short-term recall have been observed in neurogenesis-associated cognitive models
• Anxiety models — studied in corticosterone-induced models of stress and anxiety, PE22-28 demonstrated anxiolytic-consistent results in sub-chronic treatment protocols
• Cardiac safety — TREK-1 inhibition typically raises concerns around QT prolongation; however, PE22-28 did not exhibit this effect in cardiac models of treated mice

What Do Studies Say About PE22-28 Peptide?

PE22-28 is supported by well-characterised pre-clinical research literature:

• Borsotto M et al. (2015) — Frontiers in Pharmacology — Original identification of PE22-28 as a shortened Spadin analog with superior TREK-1 inhibitory potency. Demonstrated IC₅₀ of 0.12 nM versus 40–60 nM for Spadin, improved in vivo stability, and retained antidepressant activity in FST and Learned Helplessness mouse models. PMC: PMC5601071. DOI: 10.3389/fphar.2017.00564
• Djillani A et al. (2019) — Pharmacology & Therapeutics — Comprehensive review of TREK-1 blockers as antidepressant targets. Confirmed a 50% reduction in depressive behaviours in pre-clinical models via TREK-1 modulation, validated the novel antidepressant mechanism distinct from monoamine pathways, and reviewed the full Spadin/PE22-28 mechanistic landscape. ScienceDirect DOI: 10.1016/j.pharmthera.2018.09.008
• Mazella J et al. (2010) — Neuron — Foundational study identifying Spadin as the first endogenous TREK-1 channel blocker derived from sortilin cleavage, establishing the biological basis from which PE22-28 was developed.
• Heurteaux C et al. — Nature Neuroscience — Earlier foundational work confirming that TREK-1 deletion renders mice resistant to depression, establishing the rationale for TREK-1 as a target for depression-related research and validating the mechanism PE22-28 is designed to investigate.Note: All cited research relates to in-vitro and animal model studies. PE22-28 has not undergone human clinical trials and is not approved for any human, medical, or therapeutic use.

What is PE22-28 Used For in Research?

Researchers purchasing PE22-28 from UK peptides suppliers like Peptides Lab UK typically focus on:

• TREK-1 potassium channel binding, inhibition, and selectivity studies
• Depression and mood disorder pre-clinical models (FST, Learned Helplessness, corticosterone-induced depression)
• Hippocampal neurogenesis and synaptogenesis investigations
• Serotonin pathway modulation and neurotransmitter signalling research
• Post-stroke depression (PSD) and cerebral ischemia models
• Cognitive function, memory, and learning studies linked to neurogenesis
• Neuroprotection and excitotoxicity resistance investigations
• TREK-1 vs TREK-2/TRAAK/TRESK selectivity and K2P channel comparison studies
• Nootropic and neurological compound comparative analyses
• Anxiety and stress response model studies

PE22-28 vs Spadin – What’s the Difference?

Feature	PE22-28 (Mini-Spadin)	Spadin (PE12-28)
Amino Acids	7	17
TREK-1 IC₅₀	0.12 nM	40–60 nM
In Vivo Stability	Superior	Limited (~7 hours)
Onset of Effect	Rapid	Rapid
Selectivity	High	Good
Research Utility	Preferred analog	Parent compound

PE22-28 is the preferred research tool for TREK-1 investigations due to its significantly improved potency and stability profile.

Quality & Purity Assurance

Every batch of PE22-28 from Peptides Lab UK is:

• >99% pure — HPLC verified and third-party confirmed
• Supplied with a full Certificate of Analysis (COA) on request
• Lyophilised powder for maximum stability and long shelf life
• Manufactured under strict, controlled laboratory conditions
• Consistent batch-to-batch quality for reproducible research results

Why Buy PE22-28 from Peptides Lab UK?

When you buy PE22-28 peptide UK from Peptides Lab UK, you receive:

99% purity, HPLC verified and third-party tested

• Full COA documentation per batch
• Fast same-day UK dispatch with tracked delivery
• Competitive pricing with bulk research discounts available
• Trusted by researchers across the UK and Europe

Research Disclaimer: All products supplied by Peptides Lab UK are intended strictly for in-vitro laboratory research and scientific study use only. They are not intended for human consumption, veterinary use, or any medical or therapeutic application. PE22-28 has not been evaluated by the MHRA or any regulatory authority for safety or efficacy in humans or animals. All research citations on this page relate to pre-clinical in-vitro and animal model studies and do not constitute evidence of safety or therapeutic efficacy in humans. Peptides Lab UK accepts no liability for any misuse of research compounds. By purchasing, you confirm that you are a qualified researcher and that the product will be used solely within a controlled laboratory environment in compliance with all applicable UK laws, regulations, and institutional guidelines.